Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu; Zylfije Hundozi; Faton Sermaxhaj; Afrim Blyta; Nexhmedin Shala; Fisnik Jashari; Hasime Qorraj Bytyqi; Ekrem Hyseni; Ilir Kurtishi

doi:10.12659/MSM.937856

31 August 2022 : Clinical Research

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Blerim Myftiu^12ABCDEFG*, Zylfije Hundozi^12ACDF, Faton Sermaxhaj^3ABD, Afrim Blyta^1ACDF, Nexhmedin Shala^12CD, Fisnik Jashari^12C, Hasime Qorraj Bytyqi^4CDF, Ekrem Hyseni^3BC, Ilir Kurtishi^3BC

DOI: 10.12659/MSM.937856

Med Sci Monit 2022; 28:e937856

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 7 Clinical comparison between platinum-only, taxane-only, and combination groups.

Variable	None	Platinum	Taxane	Combination	Significance
Sensory symptoms	1.50	1.95	1.47	1.73	p=0.17
Motor symptoms	0.00	0.15	0.07	0.23	p=0.30
Autonomous symptoms	0.00	0.05	0.00	0.00	p=0.38
Tactile sensitivity	1.25	1.40	1.20	1.36	p=0.84
Vibration sensitivity	0.75	1.23	0.80	1.05	p=0.10
Muscle strength	0.00	0.18	0.07	0.55	p<0.05
Deep-tendon reflexes	2.00	2.77	2.30	2.55	p=0.21
Total Neuropathy Score, reduced	8.5±5.1 (N: 8)	12.1±5.8 (N: 60)	9.6±5.5 (N: 30)	11.6±6.5 (N: 22)	p=0.14

Back to the Article

Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4-6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo

Your Privacy